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Summary
In patients with growth hormone (GH) deficiency
(GHD) the diagnostic value of IGF-I levels has been
recently revisited. A normal IGF-I value does not
exclude GHD, because its secretion is complex and
depends by several factors other than GH, such as
age, nutritional status, obesity, as well as catabol-
ic illness. Due to the complexity and costs of GH
stimulation tests, several authors have analyzed
the predictive and diagnostic value of the concen-
tration of plasma IGF-I in patients suspected for
GHD. The evaluation of IGF-I is also determinant to
individualized dose-titration strategies, able to
avoid the common adult side effects of substitutive
therapy with recombinant GH. Current recommen-
dations in clinical practice for GH replacement
therapy, in GHD adults, agree on GH dosing regi-
mens to be individualized independently of body
weight using IGF-I levels as a biomarker of the
treatment. For these reasons, in a clinical setting,
appropriate normative values in different age
groups in a large healthy population must be es-
tablished in single laboratories, while, considering
the relatively small sex difference, a different refer-
ence range for sex seems not necessary. This re-
view discusses the more recent debated issues in
the literature on the role of IGF-I, as well as other
IGF system components, in the management of
adult patients with GHD.
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Introduction
Growth hormone (GH) deficiency (GHD) is nowadays a
well-recognized clinical entity. It causes abnormalities
in substrate metabolism, body composition, physical,
and psychosocial function, which improve after recom-
binant GH (rhGH) replacement therapy. GHD is sus-
pected from patient’s pathological history and from
clinical sign and symptoms of hypopituitarism (1).
Diagnosis of adult GHD is made by GH provocative
tests and the most commonly used are the insulin tol-
erance test (ITT), GH releasing hormone (GHRH) plus
arginine test and glucagon test. Different cut-off values
have been defined according to BMI (2) and the diag-
nostic value of IGF-I levels has been recently revisited
(1,2). In particular, very low IGF-I levels, in patients
with an history and/or signs and symptoms highly sus-
pected for GHD (presence of multiple pituitary hor-
mone deficits), could be sufficient to confirm the diag-
nosis (see below). IGF-I is an appropriate screening
test for GHD in young adult lean patients (<40 years,
BMI <25 kg/m2), however, normal IGF-I levels do not
rule out GHD at any age. The levels of IGF-I may de-
pend on many factors other than GH secretion: above
all, the nutritional status. Indeed, in undernourished
patients, IGF-I levels are generally low. Currently, there
are no suitable markers of GH activity alternative to
IGF-I, although, IGF-I is only one of the many GH-de-
pendent circulating peptides. Among these latter ele-
ments, the IGF binding protein 3 (IGFBP-3) and the
acid labile subunit (ALS) of the 150 kDa circulating
complex have also been proposed as alternative pa-
rameters reflecting GH secretion (3). Excluding critical-
ly ill patients, the relative independence of ALS from
substances known to affect the production of IGF-I and
IGFBP-3 supports it for a potential use as a more spe-
cific parameter indicating GH secretory status. Further
efforts are obviously necessary in order to develop
age-specific normal values for ALS.
It is known that the analytical method influences the re-
sults of GH stimulation tests, however, similar prob-
lems exist for IGF-I as well. The classical immunoas-
say method for the measurement of IGF-I concentra-
tion, with acid-ethanol extraction to avoid the interfer-
ence of binding proteins, has been widely used in the
clinical practice since the early ’80ies.
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Several papers reported studies on normal IGF-I levels
in healthy subjects (4-8): IGF-I is lowest at birth and
gradually increases with age reaching the peak in ad-
vanced puberty. In the adult state a decline of IGF-I
values is reported with increasing age. In an Italian
study, unlike other studies performed in Northern and
Central Europe, no significant differences were found
between sexes, in any group of age range, and an high
variability of IGF-I values in the oldest people (8) has
been reported as well. The gender difference observed
in some studies might probably be due to the suppres-
sive effect on IGF-I levels exerted by oral estrogens,
largely used by women in Northern Europe (7).
For these reasons, in a clinical setting, appropriate nor-
mative values in different age groups in a large healthy
population must be established in single laboratories,
while, considering the relatively small gender differ-
ence, a separate reference range for sex is not neces-
sary. Moreover, racial differences have been described
as well: black men seem to display lower levels of IGF-
BP-3 and IGF-I and a greater IGF-I/IGFBP-3 ratio than
white men across all ages, but younger than 70 (9).
This picture is probably due to a genetic background,
nutritional and social customs, physical activity and
use or abuse of specific drugs. 
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There is a variety of methods of assay and kit materi-
als available for IGF-I determination, but  the validity
and strength of reference values were demonstrated
independently of the used method for IGF-I testing
(10,11). In conclusion, additional studies are necessary
to develop age-specific reference ranges for IGF-I nor-
mal value in healthy subjects.
IGF-I diagnostic value in patients suspected of
GHD: not always GH stimuli
Due to the complex, as well as expensively, GH stimula-
tion tests, several authors have analyzed the predictive
and diagnostic value of the concentration of IGF-I in plas-
ma, in patients suspected for GHD (4,12,13). Normal val-
ue of IGF-I does not exclude GHD, because the regula-
tion of its secretion is complex and depends by several
factors (14,15). Moreover the timing of onset of GHD
(childhood vs adult), can modify IGF-I concentration, low-
er in childhood-onset than adult-onset GHD patients
(16). Therefore, in panhypopituitaric patients and in sus-
pected adult GHD patients with normal IGF-I and, with-
out confounding factors, a GH provocative test is neces-
sary to achieve the diagnosis (5,12,13,17-19) (Fig. 1).
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Figure 1 - The role of IGF-I in GHD diagnosis in naive adult patients. Cut-off values of GH peak are correct only after GHRH
+ arginine stimulation tests. As regard normal values of IGF-I the range of normality is defined for age range (as mentioned
in the text).
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Total IGF-I has good intra-individual reproducibility and
it is positively associated with the peak GH response to
provocative tests (20). Based on these studies, we
agree on the proposal that adult patients, with 3 or
more pituitary deficits and low IGF-I, provocative tests
are useless for the diagnosis of GHD. Similarly, a very
low IGF-I level, in the absence of catabolic conditions
or hypothyroidism, could be considered strongly sug-
gestive for GHD, although the most recent guidelines
still require GH stimulating tests in order to start the
treatment with rhGH (21) (Fig. 1). 
Childhood-onset GHD needs retesting in late adoles-
cence or young adult hood. In the past, this issue
raised questions about the most appropriate provoca-
tive test, as well as the cut-off value to be adopted. In
patients with GHD of irreversible nature, such as post
hypophysectomy, the simple measurement of IGF-I
concentration, off rhGH for at least 1 month, could be
sufficient. However, in presence of normal IGF-I val-
ues, a provocative test is mandatory in order to confirm
or exclude the GHD (21,22).
In the last years many authors have demonstrated that
hypopituitarism, in particular GHD, is common among
patients that have suffered from a traumatic brain in-
jury, and the prevalence may vary from 10 to 25%
(23,24). In an interesting study in a series of patients
with a documented history of moderate to severe trau-
matic brain injury the role of low IGF-I value to deter-
mine with a better accuracy the patients needing a
screening for GHD has been emphasized (25). This is
another example of a condition where IGF-I concentra-
tions may have a better diagnostic value in the future,
when the techniques of assay and the reference inter-
vals will be definitively improved.
IGF-I in GHD patients treated with rhGH replace-
ment therapy: dose titration
Dosing protocols have evolved from weight-based dos-
ing (adopted in pediatric clinical practice) to individual-
ized dose-titration strategies able to avoid the common
adult side effects, such as paresthesias, peripheral
edema, arthralgias and myalgias, caused by supra
physiological levels of IGF-I (21,26). It is well known
that rhGH therapy requires careful monitoring to
achieve maximal efficacy and to reduce potential ad-
verse events. A reliable method, useful in monitoring
patient responses to rhGH, is needed to optimize GH
dose adjustments.
Direct assessment of circulating GH levels during
rhGH treatment is useless in monitoring patient re-
sponse because GH is secreted by the pituitary in a
pulsatile fashion, with a short half-life in blood. IGF-I,
due to a more stable pattern of release (27) and a long
half-life, has an established role in the monitoring of
patient treatment (Fig. 2).
Treatment goal for adults with GHD is to reduce mor-
bidity and mortality related to the hormone deficiency.
The response to rhGH therapy in adults is variable: a
dosing protocol that is suboptimal in one patient may
be excessive in another one, while even normalization
of IGF-I can induce side effects is some adult patients.
In general, IGF-I concentrations, together with the clin-
ical picture, as well as the metabolic parameters,
should guide the physician in the therapeutic decisions
(38) (Fig. 2). Current recommendations in clinical prac-
tice for GH replacement therapy, in GHD adults, agree
on GH dosing regimens to be individualized, independ-
ently of the body weight, using IGF-I levels as a bio-
marker of the treatment (29, 30). The aim is to maintain
IGF-I levels near the 50° percentile for age or 1 SDS
above the mean value for age (1,29). 
Age and gender have to be considered for rhGH dosing.
Older patients should be treated initially with lower dos-
es, that should be increased more slowly compared with
younger subjects in order to avoid side effects, where as
younger patients need higher doses. As previously stat-
ed, women, particularly those who are taking oral estro-
gen, usually may need higher doses of rhGH (31-34). 
In panhypopituitary patients we should also take into
consideration the potential interactions with other ther-
apies, particularly replacement treatments, such as
glucocorticoids: in patients taking adequate substitu-
tive glucocorticoid therapy the response to rhGH is
higher than in patients overtreated. In the latter group
IGF-I can be reduced, probably due to the effect of cor-
tisol on GH-IGF-I axis (35).
Another factor that can influence IGF-I value during re-
placement treatment with rhGH is the Body Mass Index
(BMI). Indeed, obese compared with non-obese pa-
tients have shown larger increment in IGF-I values after
GH replacement therapy (36). By converse, low IGF-I
levels have been found in patients with GH resistance
due to malnutrition, and it is well known that while a low
protein intake is able to increase IGF-I in the presence
of adequate energy balance, there is a minimum value
of energy intake below which even an optimal protein
intake fails to obtain an increase in serum IGF-I (37).
The mechanisms through which malnutrition decreases
IGF-I value are different: reduction in the number of liv-
er GH receptors, alteration of post-receptor pathways,
reduction of circulating binding proteins, as well as oth-
er hormonal changes able to reduce IGF-I gene expres-
sion, such as insulin variation (37). 
During replacement treatment, IGF-I levels should be
monitored every 1-3 months in the phase of dose titra-
tion, and then semi annually (21). Finally, no conclu-
sive data are available regarding the optimal daily tim-
ing of GH administration (evening or morning). This as-
pect is probably secondary, however needs more sys-
tematical evaluation (30).
Some interesting studies reported the effects of rhGH
treatment on IGF-I and IGFBP-3 and demonstrated
that IGFBP-3 is less sensitive than IGF-I to GH stimu-
lation (32, 39). This phenomenon is probably due to a
presumable direct effect of IGF-I, in addition to GH, on
synthesis and release of IGFBP-3, and justifies the
reason why the response of IGFBP-3 is delayed with
respect to IGF-I (37). Therefore, in study and manage-
ment of patients affected by GHD, we should not ex-
clude a possible role also for IGFBP-3, particularly in
those situations in which we cannot have a reliable val-
ue of IGF-I.
IGF-I estimation
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Conclusion
Evaluation of IGF- I levels in patients is a crucial factor
in the diagnosis of GHD and it is used for dose adjust-
ment of rhGH replacement therapy. Due to the key role
of IGF-I in the management of GHD appropriate refer-
ence values in different age groups in a large healthy
population must be established and need to be further
investigated.
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